Region Midtjylland

The Department of Cardiology at the University clinic for cardiovascular research in Region Midtjylland focuses on conditions such as ASCVD, acute coronary syndrome, atrial fibrillation, myocardial infarction, and stroke prevention. Trials aim to test new anticoagulants, lipid‑lowering agents, and rapid self‑administered therapies to reduce major adverse cardiovascular events (MACE).

• Evaluation of novel anticoagulant therapies for stroke prevention
• Investigation of lipid‑lowering agents to reduce MACE
• Assessment of rapid self‑administered treatment for acute myocardial infarction
• Research on vasopressor strategies for hypotensive shock in emergency settings
• Study of insulin preservation strategies in type 1 diabetes with cardiovascular risk

Region Midtjylland hosts 28 active trials with 62 investigators, advancing cardiovascular care through innovative research.

Research at the site includes studies on Diffuse Large B‑Cell Lymphoma and Multiple Myeloma, evaluating chemotherapy regimens and immunoglobulin prophylaxis to improve survival and reduce infection risk.

• Comparative chemotherapy regimens for aggressive lymphoma
• Primary immunoglobulin prophylaxis to reduce infections in multiple myeloma
• Evaluation of targeted therapies in KRAS‑mutated lung cancer with lymphatic involvement

The cardiology department collaborates with hematology specialists to integrate cardiovascular safety assessments into these trials.

Trials address type 1 diabetes and related endocrine complications, testing agents such as finerenone and intensive care strategies to lower cardiovascular and renal risk.

• Intensified cardiovascular care strategies for type 1 diabetes
• Finerenone assessment for renal and heart outcomes
• Combination of insulin preservation and novel agents in newly diagnosed T1D

By linking metabolic and cardiac expertise, the site aims to reduce long‑term complications in hormonal disease patients.

Oncology research includes advanced non‑small cell lung cancer with KRAS p.G12C mutations, focusing on front‑line combinations of targeted inhibitors and immunotherapy.

• Front‑line platinum doublet with KRAS inhibitor versus immunotherapy
• Evaluation of chemotherapy combinations in advanced NSCLC
• Biomarker‑driven trials for targeted oncology therapies

The program integrates cardiac monitoring to ensure cardiovascular safety during aggressive cancer treatments.

Studies target neurological conditions such as migraine and post‑stroke management, testing CGRP antagonists for pediatric migraine and FXIa inhibitors for ischemic stroke risk reduction.

• Pediatric migraine prevention with CGRP antagonist
• Stroke risk reduction using FXIa inhibition after acute ischemic events
• Safety of sodium bicarbonate during cardiac arrest affecting neurological outcomes

Collaborative efforts with neurology aim to improve both vascular and neuro‑protective outcomes.

The site investigates metabolic risk factors, including obesity and severe hypertriglyceridemia, evaluating agents that lower triglycerides and lipoprotein(a) to curb cardiovascular events.

• Olezarsen for triglyceride lowering in high‑risk patients
• Olpasiran to reduce Lp(a) and cardiovascular events
• BI 456906 trial for weight management in obesity

Metabolic studies are coordinated with cardiology to assess combined impact on heart health.

Research on chronic rhinosinusitis with nasal polyposis compares biologic therapies, aiming to determine the most effective treatment for symptom relief and quality of life.

• Head‑to‑head comparison of biologics for nasal polyps
• Real‑world effectiveness of IL‑4/13 inhibition
• Assessment of symptom relief and quality of life outcomes

Findings support integrated care pathways that consider cardiovascular comorbidities in ENT patients.

Trials address acute critical conditions such as shock and hypotension, testing early vasopressor use versus fluid therapy and bicarbonate administration during cardiac arrest.

• Early vasopressor therapy for emergency department shock
• Bicarbonate administration during cardiac arrest
• Evaluation of hemodynamic endpoints in critical care settings

These studies aim to improve survival and reduce intensive‑care admissions for severe systemic events.

While the primary focus is cardiovascular, the site conducts investigations on respiratory outcomes in patients with heart disease, examining pulmonary complications and lung function.

• Investigations of respiratory outcomes in cardiovascular patients
• Assessment of pulmonary complications after acute coronary syndrome
• Monitoring of lung function in systemic inflammatory conditions

Integrating respiratory assessments helps capture the full spectrum of comorbidities affecting trial participants.